Revenue Potential: Apitegromab has a total revenue potential of greater than $1 billion. Scholar Rock Holding Corp ...

Scholar Rock Holding (SRRK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Etzer Darout from BMO Capital reiterated a Buy rating on the ...

H.C. Wainwright raised the firm’s price target on Scholar Rock (SRRK) to $40 from $35 and keeps a Buy rating on the shares. Scholar Rock ...

November 12, 2024--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing ...

Good morning and welcome to Scholar Rock's Third Quarter 2024 Financial Results and Business Update Call. All participants will be in listen-only mode. After the company’s prepared remarks all ...

Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report) has been given a consensus rating of “Buy” by the seven brokerages ...

Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report) by 28.2% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 748,489 shares ...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.